Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Visegrády, A.
Right arrow Articles by Keseru, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Visegrády, A.
Right arrow Articles by Keseru, G. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Application of the BD ACTOneTM Technology for the High-Throughput Screening of Gs-Coupled Receptor Antagonists

András Visegrády

Lead Discovery Unit, visegrady{at}richter.hu

András Boros

Pharmacological and Drug Safety Research, Gedeon Richter Plc, Budapest, Hungary

Zsolt Némethy

Pharmacological and Drug Safety Research, Gedeon Richter Plc, Budapest, Hungary

Béla Kiss

Pharmacological and Drug Safety Research, Gedeon Richter Plc, Budapest, Hungary

György M. Keseru

Lead Discovery Unit

A novel technology for monitoring the changes of 3,'5'-adenosine cyclic monophosphate (cAMP) in live cells suitable for drug screening relies on the use of cyclic nucleotide-gated channels as biosensors coexpressed with the appropriate target receptor. The technique (termed BD ACTOneTM) offers measurement of cAMP-dependent calcium influx or membrane depolarization with conventional fluorescent methods both in kinetic and in endpoint modes, optimal for high-throughput and subsequent compound screening. The utility of the technique is reported here based on assay development and high-throughput screening for small-molecule antagonists of the peptide parathyroid hormone 2 receptor (PTH2R). The dual-signaling properties of the receptor were retained in the recombinant system, and the observed pharmacological profile corresponded to data from radiolabeled cAMP determination. The membrane-potential-based high-throughput assay produced reproducible actives and led to the identification of several chemical scaffolds with potential utility as PTH2R ligands. (Journal of Biomolecular Screening 2007:1068-1073)

Key Words: cyclic nucleotide-gated channel • high-throughput screening • cAMP • G-protein-coupled receptor • peptide parathyroid hormone 2 receptor

Journal of Biomolecular Screening, Vol. 12, No. 8, 1068-1073 (2007)
DOI: 10.1177/1087057107309035
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
S. P. Brothers, S. A. Saldanha, T. P. Spicer, M. Cameron, B. A. Mercer, P. Chase, P. McDonald, C. Wahlestedt, and P. S. Hodder
Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening
Mol. Pharmacol., January 1, 2010; 77(1): 46 - 57.
[Abstract] [Full Text] [PDF]